- Home
- DYNX vs CMPX Comparison
DYNX vs CMPX Comparison
Compare DYNX & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYNX
- CMPX
- Stock Information
- Founded
- DYNX 2024
- CMPX 2014
- Country
- DYNX United States
- CMPX United States
- Employees
- DYNX N/A
- CMPX N/A
- Industry
- DYNX
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- DYNX
- CMPX Health Care
- Exchange
- DYNX NYSE
- CMPX Nasdaq
- Market Cap
- DYNX 219.0M
- CMPX 214.6M
- IPO Year
- DYNX 2024
- CMPX N/A
- Fundamental
- Price
- DYNX $9.81
- CMPX $2.63
- Analyst Decision
- DYNX
- CMPX Strong Buy
- Analyst Count
- DYNX 0
- CMPX 4
- Target Price
- DYNX N/A
- CMPX $13.75
- AVG Volume (30 Days)
- DYNX 12.3K
- CMPX 2.2M
- Earning Date
- DYNX 01-01-0001
- CMPX 11-12-2024
- Dividend Yield
- DYNX N/A
- CMPX N/A
- EPS Growth
- DYNX N/A
- CMPX N/A
- EPS
- DYNX N/A
- CMPX N/A
- Revenue
- DYNX $2,124,981.00
- CMPX $850,000.00
- Revenue This Year
- DYNX N/A
- CMPX N/A
- Revenue Next Year
- DYNX N/A
- CMPX $613.39
- P/E Ratio
- DYNX N/A
- CMPX N/A
- Revenue Growth
- DYNX N/A
- CMPX N/A
- 52 Week Low
- DYNX $9.91
- CMPX $0.77
- 52 Week High
- DYNX $9.99
- CMPX $2.73
- Technical
- Relative Strength Index (RSI)
- DYNX N/A
- CMPX 77.67
- Support Level
- DYNX N/A
- CMPX $2.34
- Resistance Level
- DYNX N/A
- CMPX $2.73
- Average True Range (ATR)
- DYNX 0.00
- CMPX 0.29
- MACD
- DYNX 0.00
- CMPX 0.12
- Stochastic Oscillator
- DYNX 0.00
- CMPX 93.53
About DYNX DYNAMIX CORP
Dynamix Corp is a blank check company.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.